Citations

Mayo Clinic

Showing 10 of 108522 citations.

Exercise, Hormones, and Skeletal Adaptations During Childhood and Adolescence
Laddu, Deepika , Going, Scott B. , Farr, Joshua N.

Pediatric Exercise Science | November 5, 2014 | Volume: 26 | Issue: 4 | Pages: 384-391

10.1123/pes.2014-0077 | PMID 25372373 Get It

Although primarily considered a disorder of the elderly, emerging evidence suggests the antecedents of osteoporosis are established during childhood and adolescence. A complex interplay of genetic, environmental, hormonal and behavioral factors determines skeletal development, and a greater effort is needed to identify the most critical factors that establish peak bone strength. Indeed, knowledge of modifiable factors that determine skeletal development may permit optimization of skeletal health during growth and could potentially offset reductions in bone strength with aging. The peripubertal years represent a unique period when the skeleton is particularly responsive to loading exercises, and there is now overwhelming evidence that exercise can optimize skeletal development. While this is not controversial, the most effective exercise prescription and how much investment in this prescription is needed to significantly impact bone health continues to be debated. Despite considerable progress, these issues are not easy to address, and important questions remain unresolved. This review focuses on the key determinants of skeletal development, whether exercise during childhood and adolescence should be advocated as a safe and effective strategy for optimizing peak bone strength, and whether investment in exercise early in life protects against the development of osteoporosis and fractures later in life.
Faculty Opinions recommendation of Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain.
Kaufmann, Scott H. , Dai, Haiming , Kaufmann, Scott H

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 5, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718882362.793501168 Get It

Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation
Terzi, Eleonora, Kim, W. Ray , Sánchez, William , Schmeltzer, Paul A., Andrews, James C. , Smyrk, Thomas C. , Charlton, Michael , Gores, Gregory J. , Heimbach, Julie K. , Sanchez, William

Liver Transplantation | November 5, 2014 | Volume: 21 | Issue: 2 | Pages: 248-257

10.1002/lt.24041 | PMID 25371111 Get It

Transarterial chemoembolization (TACE) is a common treatment for patients with hepatocellular carcinoma (HCC) who are awaiting liver transplantation (LT). The aim of this study was to assess the impact of multiple TACE treatments on tumor necrosis, tumor recurrence, and survival in these patients. A retrospective analysis was performed for 104 consecutive patients undergoing LT for HCC from January 2002 to December 2009 who were treated with TACE before LT. The number of TACE treatments was not associated with tumor necrosis in the explant. After a median follow‐up of 69 months (range = 0‐123 months), 14 of the 104 patients (13%) developed recurrent HCC after LT. Recurrence had a significant relationship with a short interval between the diagnosis of HCC and LT (≤6 months) in univariate and multivariate analyses [P = 0.029, odds ratio (OR) = 19.2]. Patients subjected to a single TACE treatment were more likely to experience recurrence, although this finding was not confirmed in the multivariate analysis. No significant relationship was observed between tumor necrosis in the explant and recurrence. The mean overall survival was 102.8 months (95% confidence interval = 94.9‐110.8 months) with 1‐, 3‐, and 5‐year survival rates of 91%, 89%, and 84% respectively. In the univariate survival analysis, the presence of ascites before TACE, a waiting time ≤ 9 months, and tumor characteristics at the pathological examination were statistically associated with shorter survival. In the multivariate analysis, only vascular invasion (P < 0.001, OR = 7.99) remained independently associated with shorter survival. The number of TACE treatments was not associated with survival. In conclusion, multiple TACE treatments were not associated with a higher risk of recurrence or shorter survival. Continued use of TACE should be considered as indicated if the patient and lesions are suitable for retreatment. A shorter waiting time before LT is related to an increased risk of recurrence and decreased survival after LT for HCC. These data could reflect the presence of more aggressive tumor biology and may be useful for guiding organ allocation policy to consider a minimum observation period before LT for regions with shorter wait times. Liver Transpl 21:248‐257, 2015. © 2014 AASLD.
Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies
Kenderian, Saad S. , Ruella, Marco , Gill, Saar , Kalos, Michael , Kenderian, Saad Sirop, Kenderian, Saad Sirop , Ruella, Marco

Cancer Research | November 5, 2014 | Volume: 74 | Issue: 22 | Pages: 6383-6389

10.1158/0008-5472.can-14-1530 | PMID 25371415 Get It

Abstract Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody–T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificity of antibodies with the polyfunctionality and potency of cellular immunity and are a prime example of the potential for synthetic biology to treat disease. CAR T cells overcome several of the biologic obstacles that have historically hampered immunotherapy while providing fundamental mechanistic insights into cellular immunology and revealing new challenges in genetic engineering and target selection. Results from early-phase CAR T-cell–based clinical trials demonstrate the significant potential for this approach to affect dramatic and complete clinical responses while revealing novel toxicities associated with activation of potent and specific antitumor immunity. Cancer Res; 74(22); 6383–9. ©2014 AACR.
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Patel, Tushar , Ilyas, Sumera I. , Borad, Mitesh J. , Gores, Gregory J. , Patel, Tushar

Seminars in Liver Disease | November 4, 2014 | Volume: 34 | Issue: 04 | Pages: 456-464

10.1055/s-0034-1394144 | PMID 25369307 Get It

AbstractCholangiocarcinoma (CCA) is an aggressive biliary tract malignancy with limited treatment options and low survival rates. Currently, there are no curative medical therapies for CCA. Recent advances have enhanced our understanding of the genetic basis of this disease, and elucidated therapeutically relevant targets. Therapeutic efforts in development are directed at several key pathways due to genetic aberrations including receptor tyrosine kinase pathways, mutant IDH enzymes, the PI3K-AKT-mTOR pathway, and chromatin remodeling networks. A highly desmoplastic, hypovascular stroma is characteristic of CCAs and recent work has highlighted the importance of targeting this pathway via stromal myofibroblast depletion. Future efforts should concentrate on combination therapies with action against the cancer cell and the surrounding tumor stroma. As the mutational landscape of CCA is being illuminated, molecular profiling of patient tumors will enable identification of specific mutations and the opportunity to offer directed, personalized treatment options.
Case-only exome sequencing and complex disease susceptibility gene discovery: study design considerations
Wu, Lang , Schaid, Daniel J. , Sicotte, Hugues , Wieben, Eric D. , Petersen, Gloria M. , Li, Hu

Journal of Medical Genetics | November 4, 2014 | Volume: 52 | Issue: 1 | Pages: 10-16

10.1136/jmedgenet-2014-102697 | PMID 25371537 Get It

Whole exome sequencing (WES) provides an unprecedented opportunity to identify the potential aetiological role of rare functional variants in human complex diseases. Large-scale collaborations have generated germline WES data on patients with a number of diseases, especially cancer, but less often on healthy controls under the same sequencing procedures. These data can be a valuable resource for identifying new disease susceptibility loci if study designs are appropriately applied. This review describes suggested strategies and technical considerations when focusing on case-only study designs that use WES data in complex disease scenarios. These include variant filtering based on frequency and functionality, gene prioritisation, interrogation of different data types and targeted sequencing validation. We propose that if case-only WES designs were applied in an appropriate manner, new susceptibility genes containing rare variants for human complex diseases can be detected.
Total hip replacement in patients with Down syndrome and degenerative osteoarthritis of the hip
Amanatullah, Derek F. , Rachala, Sridhar R., Trousdale, R T, Sierra, Rafael J.

The Bone & Joint Journal | November 4, 2014 | Volume: 96-B | Issue: 11 | Pages: 1455-1458

10.1302/0301-620x.96b11.34089 | PMID 25371456 Get It

Dysplasia of the hip, hypotonia, osteopenia, ligamentous laxity, and mental retardation increase the complexity of performing and managing patients with Down syndrome who require total hip replacement (THR). We identified 14 patients (six males, eight females, 21 hips) with Down syndrome and degenerative disease of the hip who underwent THR, with a minimum follow-up of two years from 1969 to 2009. In seven patients, bilateral THRs were performed while the rest had unilateral THRs. The mean clinical follow-up was 5.8 years (standard deviation (sd) 4.7; 2 to 17). The mean Harris hip score was 37.9 points (sd 7.8) pre-operatively and increased to 89.2 (sd 12.3) at final follow-up (p = 1x10-9). No patient suffered a post-operative dislocation. In three patients, four hips had revision THR for aseptic loosening at a mean follow-up of 7.7 years (sd 6.3; 3 to 17). This rate of revision THR was higher than expected. Our patients with Down syndrome benefitted clinically from THR at mid-term follow-up. Cite this article: Bone Joint J 2014;96-B:1455–8.
Does Hospital Volume Predict Outcomes and Complications After Total Shoulder Arthroplasty in the US?
Singh, Jasvinder A. , Ramachandran, Rekha , Singh, Jasvinder A

Arthritis Care & Research | November 4, 2014 | Volume: 67 | Issue: 6 | Pages: 885-890

10.1002/acr.22507 | PMID 25370499 Get It

ObjectiveTo assess the association of hospital procedure volume for total shoulder arthroplasty (TSA) with patient outcomes and complications.MethodsWe used the US Nationwide Inpatient Sample from 1998–2011 to study the association of hospital annual TSA procedure volume with patient characteristics and TSA outcomes, including discharge disposition (home versus inpatient facility), length of index hospitalization, postarthroplasty periprosthetic fracture, and revision. Annual hospital TSA volume was categorized as <5, 5–9, 10–14, 15–24, and ≥25 TSA procedures annually.ResultsPatients receiving TSA at higher volume hospitals were more likely to be female (P < 0.0001) and white (P < 0.0001). Compared to low volume hospitals (<5, 5–9, or 10–14 procedures annually), patients receiving TSA at higher volume hospitals (15–24 or ≥25 procedures annually) had significantly lower likelihood of being discharged to an inpatient medical facility: 16.5%, 13.4%, 13.0%, 12.7%, and 11.5%, respectively (P < 0.0001); hospital stay above the overall median: 46.6%, 40.4%, 36.6%, 34.4%, and 29.2%, respectively (P < 0.0001); postarthroplasty fracture: 1.2%, 0.8%, 0.9%, 0.6%, and 0.8%, respectively (P = 0.0004); blood transfusion: 8%, 7.1%, 6.7%, 7.1%, and 5.5%, respectively (P = 0.006); and TSA revision: 0.5%, 0.3%, 0.2%, 0.3%, 0.3%, respectively (P = 0.045).ConclusionIn this study, we found that higher annual hospital TSA volume was associated with better TSA outcomes in the US. These findings document the impact of annual hospital TSA volume on TSA outcomes. Patients, surgeons, and policy‐makers should be aware of these findings and take them into account in decision‐making, policy decisions, and resource allocation.
Retrievable inferior vena cava filters can be placed and removed with a high degree of success: Initial experience
Cohoon, Kevin P. , McBride, Joseph J., Friese, J., McPhail, Ian R., Friese, Jeremy L

Catheterization and Cardiovascular Interventions | November 4, 2014 | Volume: 86 | Issue: 4 | Pages: 719-725

10.1002/ccd.25716 | PMID 25367646 Get It

ObjectivesEvaluate the success rate of retrievable inferior vena cava filter (IVC) removal in a tertiary care practice.BackgroundRetrievable IVC filters became readily available in the United States following Food and Drug Administration approval in 2003, and their use has increased dramatically. They represent an attractive option for patients with contraindications to anticoagulation who may only need short‐term protection against pulmonary embolism.MethodsAll patients who had undergone placement of a retrievable IVC filter at Mayo Clinic between 2003 and 2005 were retrospectively reviewed to evaluate our initial experience with retrievable inferior vena cava filters at a large tertiary care center. Results: During a three‐year‐period of time, Mayo Clinic, Rochester, MN placed 892 IVC filters of which 460 were retrievable. Of the 460 retrievable filters placed (249 Günther Tulip®, 207 Recovery®, and 4 OptEase®), retrieval was attempted in 223 (48.5%). Of 223 initial attempts, 196 (87.9%) were initially successful and 27 (12.1%) were unsuccessful. Of the 27 unsuccessful initial retrieval attempts, 23 (85.2%) were because of the presence of significant thrombus within the filter and 4 (14.8%) were because of tilting and strut perforation. Of the 23 filters containing significant thrombus, 9 (39.1%) were later retrieved after a period of anticoagulation and resolution of the thrombus.ConclusionsRetrievable IVC filters can be removed with a high degree of success. Approximately one in ten retrievable IVC filter removal attempts may fail initially, usually because of significant thrombus within the filter. This does not preclude possible removal at a later date. © 2015 Wiley Periodicals, Inc.
Epidemiology of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus in a Predominantly White Population in the United States
Jarukitsopa, Sudumpai, Hoganson, Deana D., Crowson, Cynthia S. , Sokumbi, Olayemi , Davis, Mark D.P. , Michet, Clement J. , Matteson, Eric L. , Kremers, Hilal Maradit , Chowdhary, Vaidehi , Davis, Mark D., Maradit Kremers, Hilal, Chowdhary, Vaidehi R, Maradit Kremers, Hilal , Sokumbi, Olayemi

Arthritis Care & Research | November 4, 2014 | Volume: 67 | Issue: 6 | Pages: 817-828

10.1002/acr.22502 | PMID 25369985 Get It

Objective Epidemiologic studies comparing the incidence and prevalence of systemic lupus erythematosus (SLE) and isolated cutaneous lupus erythematosus (CLE) are few. Olmsted County, Minnesota provides a unique setting for such a study owing to resources of the Rochester Epidemiology Project. We sought to describe and compare the incidence and prevalence of SLE and CLE from 1993–2005. Methods SLE cases were identified from review of medical records and fulfilled the 1982 American College of Rheumatology classification criteria. CLE cases included patients with classic discoid lupus erythematosus, subacute CLE, lupus panniculitis, and bullous lupus erythematosus. Age‐ and sex‐adjusted incidence and prevalence were standardized to the 2000 US white population. Results The age‐ and sex‐adjusted incidence of SLE (2.9 per 100,000; 95% confidence interval [95% CI] 2.0–3.7) was similar to that of CLE (4.2 per 100,000; 95% CI 3.1–5.2, P = 0.10). However, the incidence of CLE was 3 times higher than SLE in men (2.4 versus 0.8 per 100,000; P = 0.009). The age‐ and sex‐adjusted prevalence of CLE on January 1, 2006 was higher than that of SLE (70.4 versus 30.5 per 100,000; P < 0.001). The prevalences of CLE and SLE in women were similar, but the prevalence of CLE was higher in men than in women (56.9 versus 1.6 per 100,000; P < 0.001). The incidence of CLE rose steadily with age and peaked at 60–69 years. Conclusion The incidences of CLE and SLE are similar, but CLE is more common than SLE in men and in older adults. These findings may reflect differences in genetic or environmental etiology of CLE.